Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41422 HEART TEST LABORATORIES, INC. (Exact name of Registrant as specified in its Charter) TEXAS 26-1344466 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41422 HEART TEST LABORATORIES, INC. (Exact Name of Registrant as Specified in its Charter) | TEXAS | 26-1344466 | | --- | --- | | ( State or other jurisdiction o ...

Financial Performance - The company reported no revenue for the three months ended October 31, 2022, and minimal revenue of $3,000 for the six months ended October 31, 2022, representing a decline of $4,000 or 57% compared to the same period in 2021[143]. - For the six months ended October 31, 2022, net cash used in operating activities was $2.9 million, primarily due to a net loss of $3.4 million[153]. - The company reported a net cash used in operating activities of $1.5 million for the same period in 2021[153]. - The net change in cash and cash equivalents during the six months ended October 31, 2022, was an increase of $2.2 million[152]. Expenses - Research and development expenses increased to $849,000 and $1.3 million for the three and six months ended October 31, 2022, respectively, reflecting increases of 56% and 36% compared to the same periods in 2021[146]. - Selling, general, and administrative expenses rose to $926,000 and $1.9 million for the three and six months ended October 31, 2022, representing increases of 125% and 180% compared to the same periods in 2021[147]. - The company incurred an interest expense of $33,000 and $176,000 for the three and six months ended October 31, 2022, related to its loan and security agreements[148]. Product Development - The MyoVista device, which is pending FDA clearance, aims to enhance ECG's clinical utility in detecting cardiac dysfunction, particularly in frontline healthcare settings[123]. - The company has entered into a multi-year collaboration agreement with Rutgers University to develop AI-based ECG algorithms, expected to accelerate product development[133]. - The company is partially through a pivotal clinical validation study for the MyoVista device, with a revised FDA De Novo submission expected later in the fiscal year ending April 30, 2023[131]. - The MyoVista device is classified as a Class II medical device by the FDA, requiring De Novo premarket review for clearance[131]. Financial Position - As of October 31, 2022, the company had approximately $3.1 million in cash, an increase of $2.2 million from $918,000 as of April 30, 2022[150]. - The company completed its IPO on June 17, 2022, raising approximately $5.2 million in net proceeds after expenses[151]. - Net cash provided by financing activities was $5.1 million during the six months ended October 31, 2022, mainly from the IPO[154]. - The company experienced a net cash provided by financing activities of $1.1 million during the six months ended October 31, 2021[154]. Risks and Concerns - The company has experienced recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern[132]. - The company cannot assure the successful sale of future equity and debt securities on acceptable terms[149]. Intellectual Property - The company was granted two patents in September and October 2022, enhancing its intellectual property portfolio related to ECG technology[136]. Future Plans - The company plans to continue significant capital investment in R&D, clinical studies, and go-to-market strategies[149]. - There have been no material changes to the company's critical accounting policies and estimates[155].

Heart Test Laboratories, Inc. Nasdaq: HSCS MyoVista® Wavelet ECG Game Changing AI Technology for the Early Detection of Heart Disease. Not FDA Cleared or Approved AI + Advanced Signal Processing - Designed to Revolutionize ECG for Heart Screening October 26, 2022 AI and Wavelet Signal Processing INVESTOR OVERVIEW SAFE HARBOR Certain data in this presentation was obtained from various external sources, and neither "HeartSciences" or the "Company" nor its affiliates or representatives has verified such data w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41422 HEART TEST LABORATORIES, INC. (Exact Name of Registrant as Specified in its Charter) TEXAS 26-1344466 ( State or other jurisdiction of incorporation or organi ...

Table of Contents Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number 001-41422 HEART TEST LABORATORIES, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdictio ...